X4 Pharmaceuticals (XFOR) Net Cash Flow Growth (1y) (2018 - 2026)
Powered by 
Analysis
X4 Pharmaceuticals (XFOR) Net Cash Flow Growth (1y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 93.66% |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | -323.06% |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | 248.11% |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | 195.58% |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | -517.34% |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | -88.52% |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn | 75.60% |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 3,465.10% |
| 10 | X4 Pharmaceuticals | 510.43 Mn | 315.33 Mn | 7.19 Mn | -1,776.08% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,776.08% |
| Mar 31, 2026 | 97.77% |
| Dec 31, 2025 | 455.40% |
| Sep 30, 2025 | 160.86% |
| Jun 30, 2025 | -102.18% |
| Mar 31, 2025 | 60.16% |
| Dec 31, 2024 | -27.70% |
| Sep 30, 2024 | 5.29% |
| Jun 30, 2024 | 220.90% |
| Mar 31, 2024 | -35.87% |
| Dec 31, 2023 | -178.24% |
| Sep 30, 2023 | -261.51% |
| Jun 30, 2023 | 187.78% |
| Mar 31, 2023 | -87.28% |
| Dec 31, 2022 | 654.31% |
| Sep 30, 2022 | 274.92% |
| Jun 30, 2022 | 6.67% |
| Mar 31, 2022 | -142.37% |
| Dec 31, 2021 | 154.08% |
| Sep 30, 2021 | -23.60% |